The specific apoptotic role of T11TS has been well established in glioma animal models. T11TS specifically induces the glioma cells to die an apoptotic death via immune cross-talk with the two intracranial immune competent cells-microglia and the brain-infiltrating lymphocytes. To unearth the molecular cascades operative within the glioma cells and to some extent in the two interacting immunocytes, we had initiated studies where preliminary findings not only had indicated the involvement of death receptors but had also hinted to the involvement of other apoptotic regulators. Hence, to identify the molecular pathway of apoptosis involving other apoptotic regulators in the three cell types, the cells were studied for the intrinsic apoptotic death regulators that were engaged to maintain the mitochondrial membrane integrity. The proteins that were selected could be divided into three broad classes-the Bcl-2 family of proteins-Bid, Bax and Bcl-2; the guardian of the genome p53 and the proteins downstream of mitochondria-Apaf-1, cytochrome c, caspase-9 and caspase-3. Activated Bid as well as maximal p53 expression was observed in the first dose of T11TS thus dually activating the pro-apoptotic Bax in the first and second dose in the glioma cells. Concurrently, the pro-survival protein Bcl-2's expression level was very much down-regulated in the same two doses favoring the internal microenvironment to proceed for apoptosis. High expression of cytochrome c and Apaf-1 and the presence of active caspase-9 and active caspase-3 in all the T11TS-treated tumor-bearing groups further adjudicated apoptosis of the glioma cells with clear involvement of mitochondrial death pathway in the T11TS-treated animals. Even though expression of the apoptotic regulators remained more or less the same indicating the involvement of mitochondria in the two interacting immunocytes, the intensity of expression of these proteins was much lower than the tumor cells. The present work focuses on the mechanistic approach of how T11TS mediates apoptosis and hence is the first approach of its kind in the field of immunology where the immunotherapeutic molecule's mode of action has been worked out.
Introduction
T11TS/SLFA-3, a membrane glycoprotein isolated from sheep erythrocytes, reverses the immune-suppressed state of brain tumor-induced animals by boosting the functional status of the immune cells. As T11TS acts as a ligand of CD2 receptor on immunocytes, the complete reversal from the hyperplastic state to normal cellular homeostasis found in a highly invasive and 'difficult to treat' glioma model signifies the importance of exogenous administration of T11TS/SLFA-3 as an immunotherapeutic agent. Our further studies with T11TS proved it to be a specific apoptotic inducer of the brain tumor (glioma) cells (1) (2) (3) . While delineating the apoptotic role of T11TS, we found that the two interacting immunocytes that actively took part in glioma apoptosis were the microglia and the brain-infiltrating lymphocytes (BILs). However, during the process of glioma apoptosis, the interacting immunocytes were to some extent affected and a very low population of both microglia and BIL underwent apoptotic death.
There are two basic pathways of apoptosis viz the extrinsic and the intrinsic pathways. Extrinsic apoptotic signaling is mediated by the activation of 'death receptors' (DRs) after ligation with specific death ligands, ultimately culminating in activation of caspase-8 followed by downstream effector caspase activation. However, in the intrinsic pathway, the apoptotic signals are amplified via mitochondria-dependent apoptotic regulators. The link between the DR signaling cascade and the mitochondria is provided by the Bcl-2 family member, Bid (4) (5) (6) (7) . Cleavage of cytosolic p22 Bid by caspase-8 generates a p15 C-terminal fragment that translocates to the mitochondria. Truncated p15 Bid (tBid) now inserts into the membrane followed by cytochrome c release from the mitochondria. Recently, it has also been proposed that Bid cooperates with Bax (a pro-apoptotic member of the Bcl-2 family) to cause mitochondrial dysfunction (8) . The BH3 domain of Bid can bind to the pocket of Bax, and BH3 mutations that disrupted this interaction also crippled Bid's killing capacity (9) . This suggests several possibilities, among them that Bid serves as a chaperone for Bax. Alternatively, Bid might induce a conformational change that enables Bax to target and integrate into mitochondrial membranes. However, the involvement of Bax in the apoptotic pathway is also associated with p53 and Bcl-2. Previous studies have shown that, by binding to the promotor region of bax, wild-type p53 increases Bax expression with resultant apoptosis (10) (11) (12) . The bax gene is an apoptosispromoting member while bcl-2 is a survival-promoting member of the bcl-2 gene family (13) . The Bcl-2 protein is known to form heterodimers with the Bax protein in vivo and the molar ratio of Bcl-2 to Bax determines whether apoptosis is induced or inhibited in several tissues (14) . Thus, activation of Bax precedes p53 up-regulation and Bcl-2 down-regulation.
Once cytochrome c is released in the cytosol either by Bid alone or by conjugation with Bax, cytochrome c then binds to monomeric Apaf-1. Apaf-1 consists of three functional domains: an N-terminal caspase-recruitment domain (CARD), a central nucleotide-binding domain and 12-13 WD-40 repeats at the C-terminus of the molecule. However, the binding of cytochrome c, which is not dependent on the presence of nucleotide, increases Apaf-1 affinity for dATP/ ATP by ;10-fold, perhaps by opening up the nucleotide binding site or stabilizing the bound nucleotide to Apaf-1 (15) . The binding of nucleotide to the Apaf-1-cytochrome c complex triggers its oligomerization to form the apoptosome, a multimeric wheel-like Apaf-1 and cytochrome c complex (16) . The CARDs of Apaf-1 become exposed in the apoptosome, which subsequently recruit multiple procaspase-9 molecules to the complex and facilitate their auto-activation. Only the caspase-9 bound to the apoptosome is able to efficiently cleave and activate downstream executioner caspases such as caspase-3 (17) .
Our previous apoptotic results had shown maximal glioma apoptosis in the second and the third dose of T11TS while studies with the DR pathway showed it to be operative only in first dose. These findings clearly indicated the involvement of other death regulators in the second and final dose of T11TS. Henceforth, in the next phase, we tried to address the questions-whether T11TS-mediated apoptosis involved p53, the proteins of the Bcl-2 family and the apoptosomal proteins. For this purpose, the three interacting cells viz tumor cells, BILs and microglia were assayed for the said proteins. Thus, the present work will address the apoptotic cascades operating within the tumor cells and also the probable pathway of apoptosis operative within the interacting immunocytes to adjudge whether the cascades within the interacting immunocytes simulated the pathways operative within the tumor cells.
Methods

Reagents and chemicals
RPMI 1640 medium, fetal bovine serum, streptomycin and penicillin were purchased from Gibco BRL (Gaithersburg, MD, USA). Ethyl nitrosourea, RNase A, proteinase K, agarose, diethylaminoethyl cellulose (DEAE), ethidium bromide, collagenase I and IV, hyaluronidase, DNase and soyabean trypsin inhibitor were purchased from Sigma (St Louis, MO, USA). Percoll was obtained from Pharmacia Biotech and Annexin V Kit was obtained from ApoAlert, Becton Dickinson (San Jose, CA, USA). The remaining chemicals were purchased from local firms (India) and were of highest purity grade.
Antibodies
Rat monoclonal antibodies specific for Bax, Bcl-2, Apaf-1, caspase-9 and caspase-3 were purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA The directly labeled antibody employed was mouse FITC-conjugated anti-rat p53 (Pharmingen, BD Biosciences) and mouse FITC-conjugated anti-rat-cytochrome c (Santa Cruz Biotechnology). The secondary antibody employed was FITC-conjugated sheep anti-mouse IgG 1 (Pharmingen, BD Biosciences) and PE-conjugated sheep anti-mouse IgG 1 (Pharmingen, BD Biosciences). The primary and the secondary antibodies were diluted in PBS/azide (1% FBS, 1% sodium azide in PBS) plus 10% autologous rat serum (18) .
Animals
Healthy newborn Druckray rats, 2-3 days old of both sexes along with the mother, were maintained in our laboratory for the purpose of investigations. The animals consisting of eight animals in each group were weaned at 30 days of age and housed separately in isolated cages. All animals were fed autoclaved Hind Lever pellet and water ad libitum and housed in a room with ambient temperature of 22°C in 12 h light/darkness cycle. The animals were grouped into five groups in batches of eight for each experimental group, which are as follows:
(1) (N): normal control, (2) (ENU): 3-5 days old neonatal animals injected with ethyl nitrosourea (ENU) intra-peritoneally (i.p.), (3) (ET1): 7-month old ENU-treated animal's injected (i.p.) with first dose of T11TS, (4) (ET2): 7-month old ENU-treated animal's injected (i.p.) with first and second dose of T11TS, (5) (ET3): 7-month old ENU-treated animal's injected (i.p.) with first, second and third dose of T11TS at an interval of 6 days for each dose.
Rats were examined daily and weighed weekly throughout the experimental period. Maintenance and animal experiment procedures strictly followed 'Principles of Laboratory Animal Care' (NIH publication no. 85-23, revised in 1985) and also local 'Ethical Regulations'.
Induction of brain tumor with ENU
N-N-ethyl nitrosourea (ENU) was freshly prepared by dissolving 10 mg ml À1 in sterile saline and adjusting the pH to 4.5 with crystalline ascorbic acid. ENU was injected i.p. to newborn rats (3-5 days old) with a dose of 80 mg kg À1 body weight (19) (20) (21) (22) .
Isolation of T11TS and administration in animals
The glycopeptide T11TS/SLFA-3 was isolated from sheep red blood cell (SRBC) membrane as described previously (23, 24) . Briefly, 1 ml of packed cell volume of SRBC was trypsinized (25 lg per 1 ml) for 25 min at 37°C followed by nonspecific protein precipitation using 25% trichloroacetic acid and then neutralized with NaOH. The glycoprotein was separated from neutral peptides by ion exchange chromatography on a DEAE cellulose column (1.5 3 8 cm) previously equilibrated with 0.05 M formate buffer, pH 6.8. The acidic glycopeptide was then eluted with a five chambered gradient system containing 1 ml each of (i) water, (ii) 0.05 M formic acid, (iii) 0.2 M formic acid, (iv) 0.4 M formic acid and (v) 0.4 M formic acid in 0.3 M sodium chloride. Finally, elute fraction III was selected as the fraction of choice by complete rosette inhibition. The first dose of 1 ml of T11TS was administered in rats i.p. from the third elute fraction (EF III), which was followed by second booster dose on the sixth day and third booster dose on the 12 day, making a dose schedule of 1, 2 and 3 ml to the ET1, ET2 and ET3 animals, respectively.
After isolation of T11TS by ion-exchange chromatography with DEAE cellulose, protein content in the third elute containing maximum amount of T11TS was determined by Lowry's method, which was observed to be 50 mg ml À1 and 0.4 mg kg À1 body weight. SDS-PAGE of third elute produced a single band and periodic acid-Schiff staining confirmed the glycoprotein nature of the molecule (1-3). The principal amino acid present in the glycopeptide is serine, with significant amounts of lysine and glycine and to a lesser extent, aspartic acid, alanine and threonine are also found. Carbohydrate comprises nearly two-thirds of the glycopeptide on molar basis. Galactose is the principal monosaccharide, with sialic acid, galactosamine and glucosamine being present in about half the amount. The third elute fraction was further purified by HPLC and three to four major peaks were obtained. Recent mass spectroscopic studies that are being conducted with the third elute fraction, however, point to the presence of more peptide fragments (S. Chatterjee, S. Acharya, P. Kumar, S. Chaudhuri, M. Bhattacharjee and S. Chaudhuri, unpublished data).
Isolation of intracranial immune cells
Tumor cell isolation Four to five consecutive 5 lm sections were cut from the tumor susceptible area of the rat brain and the central section was stained by hematoxyline and eosin. Completely neoplastic areas as appropriate to the histopathological diagnosis and not contaminated by the normal tissue were marked out in the stained slide by the experienced pathologist and the same area was microdissected from the other slide and the scrapings were stored. Then, the microdissected tumor mass was dissociated by enzyme digestion [collagenase (0.03%) and DNase (0.01%)] in Hank's BBS. Finally, the cell suspensions were centrifuged at 80 3 g for 10 min and thereafter re-dispersed in cell culture medium containing 10% FBS. A drop of cell suspension was microscopically examined to rule out the possibility that either because of the nature of the selected tissue or as a consequence of the isolation procedure it is contaminated with the normal brain cells or cellular debris (3, 25, 26) .
Brain infiltrating lymphocytes To prepare the single-cell suspension of brain, the whole brain was minced and passed through a 80 gauge wire mesh and then the cells were incubated with collagenase I and IV (0.05 mg ml À1 ), hyaluronidase (0.025 mg ml À1 ), soybean trypsin inhibitor (0.2 TIU ml À1 ) and DNase I (0.01 mg ml À1 ) dissolved in PBS for 15 min at 37°C (27) . The cell suspension (;5 3 10 7 cells ml À1 ) was then applied over a differential Percoll density gradient of 60/50/40/30% and subjected to centrifuge for 30 min. A thin band was observed in between the interface of 40/30% gradient of Percoll. This band was collected carefully and washed thrice with PBS and re-suspended in RPMI 1640 for further functional analysis. These isolated cells from all the experimental animal groups were characterized by anti-CD3 monoclonal antibody to ascertain the purity of the lymphocytes in the isolated cell populations.
Intracranial microglia The intracranial immune reactive microglial cells were also isolated from each animal group as described previously (28) . Briefly, single-cell suspension of whole brain was incubated with collagenase (250 lg ml
À1
) and DNase I (250 lg ml À1 ) (Sigma) at 37°C for 45 min each. Then, cell suspensions were layered on 30/60% percoll gradients at 1000 3 g for 25 min (29) and brain mononuclear cells were collected from the interface. The mononuclear cell suspensions were then laid on a plastic Petri dish (Corning, NY, USA), incubated for 30 min in a CO 2 incubator, adherent cells washed out with PBS-EDTA and again layered on 20/30% Percoll gradient and centrifuged for 20 min at 2500 3 g. Cells were removed from the interface, washed thrice with PBS and finally re-suspended in RPMI 1640 media (Sigma). The microglial cells were characterized depending on their surface receptor expression (CD11b+, MHC class II+, CD4+, GFAPÀ) as described in our previous work (30) .
Analysis of apoptosis of glioma cells, BIL and microglia
Annexin V assay for the determination of membrane flip-flop of phosphatidylserine One of the earliest events in the apoptotic cascade is the exposure of phosphatidylserine (PS) on the plasma membrane (31) . The ApoAlert-Annexin V kit (Clontech, Palo Alto, CA, USA) was used to decipher the number of apoptotic cells in microglia, BILs and tumor cells isolated from different animal groups along with the glial cells isolated from normal animals which served as normal control. Briefly, 1 3 10 6 cells were taken and centrifuged at 1000 3 g for 5 min. It was then re-suspended in 100 ml of Annexin V-binding buffer and 5 ml of Annexin V-PE. After gentle mixing, it was incubated in room temperature in dark for 15 min. Then 400 ml of Annexin V-binding buffer was again added followed by gentle mixing and the record of cellular fluorescence was taken in FACS Vantage (Becton Dickinson) using laser emitting excitation light at 488 nm and the signal could be detected in the red (FL-2) channel (32) .
Apoptotic cells were also identified by their morphology as described in our previous studies. To further verify apoptosis occurring within the tumor cells as well as in BIL and Mg, DNA ladder, Terminal deoxynucleotidyl transferase dUTP nick end labeling assay, PI FACS studies and DNA fragmentation studies by 5-bromo-2-deoxyuridine ELISA had also been conducted (22, 23) .
Analysis of apoptotic proteins in the three cells: glioma cells, BIL and microglia
Western blotting Isolated brain tumor cells, BILs and microglial cells were taken. Cells were washed once with ice-cold PBS and lysed in NP-40 cell lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40) by incubating for 30 min on ice (2 3 10 7 cells ml À1 of lysis buffer). After centrifugation at 15 000 r.p.m. for 15 min, extracted proteins were separated on a 12 or 15% SDS-polyacrylamide gel and electrophoretically transferred to a polyvinylidene fluoride membrane (Immunobillon, Millipore). The membrane was blocked with 5% non-fat milk-TBST (10 mM Tris-HCl, 0.15 M NaCl, 8 mM sodium azide, 0.05% Tween-20, pH 8.0) containing 5% skim milk for 1 h at room temperature, and each primary antibody (diluted 1:1000 in blocking buffer) was applied overnight at 4°C in the same blocking solution. Anticaspase-3 antibody, anti-caspase-9 antibody and anti-Bid antibody were purchased from Santa Cruz Biochemicals (Santa Cruz, CA, USA). After incubation, membranes were washed with TBST and again incubated with anti-rat IgG-AP conjugate (diluted 1:10 000 in blocking buffer) for 1 h in blocking buffer at room temperature and washed four times for 5 min (per wash with TBST at room temperature). The membrane was then incubated with 5-bromo-4-chloro-3#-indolyphosphate p-toluidine salt-nitro-blue tetrazolium chloride substrate. After ;20-30 min when the band begins to appear, (careful vigilance was made as the reaction time varied), the membrane was then rinsed with distilled water to stop further development. The membrane was then scanned by an HP scanner. For every loading, b-actin was used as the loading control.
Labeling of cells and flow cytometric analysis Respective cell populations of ;1 3 10 7 cells ml À1 were treated with 0.3% ice cold paraformaldehyde in PBS at 4°C for an hour. Cells were then washed with PBS and permeabilized by being gently re-suspended in 0.5% Triton-X 100 in PBS and incubated at 4°C for 30 min. After washing, the treated cell preparation was collected for p53, Bax and Bcl-2 mAb tagging. The cell population of each cell type was divided into three batches. First batch of glioma, BIL and microglia at a concentration of 1-2 3 10 7 cells ml À1 were tagged with 50 ll of diluted (1:100) FITC-conjugated mouse anti-p53 (cross-reactive with rat) mAb for 30 min at 4°C in dark, washed and resuspended at PBS for analysis. Next two batches of cell containing equal amount and concentration of cells for each cell types were incubated with 50 ll of diluted (1:100) primary mAb of Bcl-2 and Bax for 30 min, washed and gently resuspended in PBS. In a second set of experiment, respective cell populations of ;1 3 10 7 cells ml À1 of each cell type was divided into two batches and prepared as above for primary antibody tagging and tagged with 50 ll of diluted (1:100) FITC-conjugated mouse anti-cytochrome c (cross-reactive with rat mAb) (in dark) while the other with Apaf-1 for 30 min at 4°C, washed and gently re-suspended in PBS.
The cells tagged with FITC-conjugated-p53 and FITCconjugated-mouse anti-cytochrome c was directly subjected to flow cytometric analysis. Apaf-1 was tagged with FITCconjugated secondary mAb while the other cell suspensions were tagged with compatible PE-conjugated secondary mAb and again incubated for 30 min at 4°C in the dark. Isotype control was FITC-conjugated mouse IgG 1 j or PE-conjugated mouse IgG 1 j as applicable. After incubating, the cells were re-suspended in PBS and subjected to flow cytometric analysis in a FACS caliber (Becton Dickinson). For each sample, 40 000 events were scored. For the intracellular antigen labeling, the Ig control sample values were subtracted from all other sample values to remove FITC or the PE background fluorescence.
Statistical analysis
The data of Annexin V and apoptotic protein expression studies with flow cytometry were analyzed for using t-test for paired observations of small single groups by difference method. The computed t score was then compared with the critical t scores with the same df. The difference between the paired observations was considered significant if the computed t equaled or exceeded the critical t for the chosen level of significance (P < a). On the contrary, the difference was considered not significant if the computed t was lower than the critical t for the chosen significance level (P > a). All results were evaluated statistically by applying the SPSS-PC package (version 9.0, SPSS, Chicago, IL, USA).
Results
Analysis of apoptosis in three interacting candidate cells: glioma, BIL and microglia
Phosphatidylserine exposure (Annexin V assay) Annexin V assay was done for the determination of apoptosis in the interacting cells. The externalization of PS increases slightly in ENU-(4.12 6 0.254%) induced condition compared with the normal group (1.42 6 0.252%). With the first dose of T11TS administration (29.71 6 0.254%), Annexin V-positive cells increased significantly (P < 0.001) in a linear fashion from tumor-bearing group. The second (56.11 6 0.257%) and third (81.31 6 0.259%) dose showed a further significant rise (P < 0.001) in Annexin V-expressing cell population with the number of PS-positive cells being maximally observed in the animal group that received three consecutive booster doses of T11TS (Fig. 1AI-AV) .
From normal animals (7.65 6 0.245%), slight increase of apoptosis of BIL was observed in tumorigenic condition (8.42 6 0.505%). With the first dose of T11TS (26.26 6 1.095%), apoptotic BIL increased following which Annexin V expression decreases in second dose (4.12 6 0.439%) signifying a decrease in BIL's apoptosis. However, in the third and final dose (26.8 6 1.11%), BIL's apoptosis again increased (Fig. 1BI-BV) .
For microglia, highest apoptosis was observed in tumorbearing animals (10.62 6 0.23%) as compared with normal (4.8 6 0.495%). However, with the three consecutive doses of T11TS (ET1 9.22 6 0.43%, ET2 8.25 6 0.385% and ET3 5.3 6 0.31%), the Annexin V expression of microglia decreases to a near normal level signifying a steady renewal of the microglial cell population (Fig. 1CI-CV) .
Thus, in this experiment it was observed that T11TS induces apoptosis of the brain tumor cells in a steep linear fashion. In case of the BILs, T11TS induces apoptosis of BIL to Fig. 1 . Annexin V expression to measure apoptosis in the glioma cells before and after administration of T11TS. The Annexin V expressions of the interacting immunocytes were also measured. Annexin V expression increased gradually in a dose-dependent manner in glioma cells on administration of T11TS. (A.I) Brain cells of normal animals (normal glial cells 1.42 6 0.252%), (A.II) brain tumor cells of 7-month-old ENU animals (ENU 1.42 6 0.252%), (A.III) cells isolated from animals after administration of first dose of T11TS in 7-month-old tumor-bearing animals (ET1 29.71 6 0.254%), (A.IV) cells isolated from animals after administration of two booster dose of T11TS at 6-day interval (ET2 56.11 6 0.257%) and (A.V) cells isolated from animals after administration of three booster dose at 6-day interval (ET3 81.31 6 0.259%). (B.I) BILs isolated form normal animals (normal BIL 7.65 6 0.245%), (B.II) BIL isolated from ENU (ENU BIL 8.42 6 0.505%), (B.III) BIL isolated from ET1 animals (ET1 BIL 26.26 6 1.095%), (B.IV) BIL isolated from ET2 animals (ET2 BIL 4.12 6 0.43%) and (B.V) BIL isolated from ET3 animals (ET3 BIL 26.8 6 1.11%). (C.I) microglia isolated form normal animals (normal microglia 4.8 6 0.495%), (C.II) microglia isolated from ENU (ENU microglia 10.62 6 0.23%), (C.III) microglia isolated from ET1 animals (ET1 microglia 9.22 6 0.43%), (C.IV) microglia isolated from ET2 animals (ET2 microglia 8.25 6 0.385%) and (C.V) microglia isolated from ET3 animals (ET3 microglia 5.3 6 0.31%).
maintain its homeostatic level while in case of microglia, the apoptotic turnover of the cell was very low maintaining a steady level just above the base line (Fig. 2) .
Analysis of the apoptotic proteins in the three cells: glioma, BIL and microglia FACS analysis p53 protein expression. To investigate the possible role of p53 in T11TS-induced apoptosis of the tumor cells, we assayed the expression of the wild-type p53 protein in glioma cells and the two immunocytes. In tumor cells, cytoplasmic presence of p53 protein decreased significantly in ENU toxicity (5.66 6 0.015%) as compared with normal (15.85 6 1.12%). The p53 protein expression then significantly (P < 0.001) and maximally increases in the first dose of T11TS (31.65 6 2.81%) after which the p53 expression level falls in next two doses (ET2 13.6 6 1.19% and ET3 12.6 6 1.18%) and reaches the normal value (Fig. 3AI-AV) .
For BILs, the intracellular presence of p53 protein was quite high in normal animals (20.94 6 1.91%), which however decreased insignificantly in tumor-bearing animals (18.12 6 1.32%). Simulating the p53 expression pattern in glioma cells, in case of the infiltrating lymphocytes, a rise in p53 level in the first dose (23.35 6 2.01%), followed by a decline in the second dose (19.82 6 1.51%) and a rise in its expression in the third dose (28.71 6 2.11%) was observed ( Fig. 3BI-BV) . For microglial cell also cytosolic p53 protein expression was high in normal animals (11.41 6 1.4%) when compared with tumor-bearing animals (9.65 6 0.91%). With the first dose of T11TS (23.44 6 1.97%), a maximal increase of the protein level was observed followed by a drop of the p53 level in the second dose (12.92 6 1.18%) where after the expression level of the protein again increased in the third dose (17.91 6 1.29%) (Fig. 3CI-CV) . Thus, expression pattern of the p53 protein was more or less similar in the three cell types where in each case maximal p53 expression was observed in the first dose after which the expression level declines.
Bax protein expression. Several pathways mediate p53-induced apoptosis and one of these involves the Bax and Bcl-2 proteins. Bax protein is a p53 target and a pro-apoptotic member of the Bcl-2 family. Thus to confirm whether or not p53-mediated Bax activation operates we studied the expression of Bax. In glioma, the expression of Bax decreased in ENU condition (21.18 6 1.62%) when compared with normal (29.39 6 1.82%). With consecutive doses of T11TS, Bax expression level gradually increases with maximal expression being found in second dose (ET1 38.21 6 2.25%, ET2 67.51 6 4.67% and ET3 54.16 6 3.18%) (Fig. 4AI-AV) .
Both BILs and microglia showed fluctuation in Bax expression, which was more or less similar to the Bax expression in glioma cells. However, the overall protein expression level was higher in both BIL and microglia than in glioma cells. Bax expression increased insignificantly in ENU toxicity (57.64 6 3.99%) when compared with normal animals (44.16 6 3.01%). But with T11TS administration, Bax expression steadily increased in the first (65.63 6 4.25%) and second (72.67 6 5.12%) dose followed by a decline in the third dose (62.71 6 4.05%) (Fig. 4BI-BV) .
With respect to normal microglia (44.99 6 3.01%), Bax expression increased slightly in ENU condition (57.61 6 1.01%). With first dose of T11TS (58.5 6 4.11%), Bax expression increased significantly from tumor-bearing group following which Bax expression again increased in the second dose (76.59 6 5.28%). In the third and final dose (68.69 6 4.96%), Bax expression showed a sharp decline (Fig. 4CI-CV) .
Bcl-2 protein expression. The anti-apoptotic member of the Bcl-2 family such as Bcl-2 itself, which is transcriptionally suppressed by p53 once apoptosis starts, preserves the integrity of the mitochondrial membrane and hence promotes survival. Obviously, the next protein that we studied was Bcl-2. Though the expression level of the protein is low, it showed definite modulatory effect to control apoptosis in the cells. In glioma, the expression of Bcl-2 was highest in ENU condition (30.07 6 2.65%) when compared with normal (5.86 6 0.07%) and the three treated doses of T11TS. With three consecutive doses of T11TS, its expression level gradually decreases to near normal level (8.26 6 0.09%, 7.73 6 0.06% and 4.43 6 0.03% for ET1, ET2 and ET3, respectively) where in the third dose of T11TS, the expression level of Bcl-2 decreases even below the normal value (Fig. 5AI-AV) .
BILs showed fluctuation in Bcl-2 expression, which was to some extent opposite to the Bcl-2 expression in glioma cells. In normal infiltrating lymphocytes (20.82 6 1.89%), Bcl-2 expression was quite high, which significantly decreased maximally in ENU (8.67 6 1.08%). But with first dose of T11TS (21.07 6 1.97%), it again increased and surpassed the normal value but subsequently decreased in the next two doses (ET2 14.97 6 1.18% and ET3 16.69 6 1.19%) (Fig. 5BI-BV) .
In case of normal microglia, Bcl-2 expression was high in normal animals (10.32 6 1.11%), which decreased to minimal level in ENU toxicity (5.15 6 1.01%). Then in the three consecutive doses viz ET1, ET2 and ET3 (ET1 7.38 6 1.08%, ET2 14.97 6 1.18% and ET3 16.69 6 1.19%), microglia recovered its Bcl-2 level steadily while in the third dose Bcl-2 expression surpassed the normal value ( Fig. 5CI-CV) .
Cytochrome c protein expression. Apoptotic cues induce the activation of Bax, which subsequently translocates from the cytosol to the mitochondrial membrane. Bax now oligomerizes on the mitochondrial membrane thereby disrupting the mitochondrial membrane integrity followed by cytochrome c release and caspase activation. Simultaneously Bid, another pro-apoptotic member of Bcl-2 family, once activated and truncated (analyzed by WB assay as described below) following activation can also induce the release of cytochrome c from the mitochondria. Bid thus cooperates with Bax to cause mitochondrial dysfunction. Hence evidently, the next molecule to be studied in the sequence was the Fig. 3 . p53 expression of the three cells viz glioma, BIL and microglia was assayed to find out its probable role in T11TS-mediated specific apoptosis of the tumor cells and of its role if any in the regulatory death of the BIL and Mg. p53 expression was found to be maximum with the first dose of T11TS in glioma cells. (A.I) Brain cells of normal animals (normal glial cells 15.85 6 1.12%), (A.II) brain tumor cells of 7-month-old ENU (ENU 5.66 6 0.015%), (A.III) cells isolated from animals after administration of first dose of T11TS in 7-month-old tumor-bearing animals (ET1 31.65 6 2.81%), (A.IV) cells isolated from animals after administration of two booster dose of T11TS at 6-day interval (ET2 13.6 6 1.19%) and (A.V) cells isolated from animals after administration of three booster dose at 6-day interval (ET3 12.6 6 1.18%). (B.I) BILs isolated form normal animals (normal BIL 20.94 6 1.91%), (B.II) BIL isolated from ENU (ENU BIL 18.12 6 1.32%), (B.III) BIL isolated from ET1 animals (ET1 BIL 23.35 6 2.01%), (B.IV) BIL isolated from ET2 animals (ET2 BIL 19.82 6 1.51%) and (B.V) BIL isolated from ET3 animals (ET3 BIL 28.71 6 2.11%). (C.I) microglia isolated form normal animals (normal microglia 11.41 6 1.4%), (C.II) microglia isolated from ENU (ENU microglia 9.65 6 0.91%), (C.III) microglia isolated from ET1 animals (ET1 microglia 23.44 6 1.97%), (C.IV) microglia isolated from ET2 animals (ET2 microglia 12.92 6 1.18%) and (C.V) microglia isolated from ET3 animals (ET3 microglia 17.91 6 1.29%).
inter-mitochondrial membrane protein cytochrome c. In case of brain cells, an insignificant rise in cytochrome c expression was observed in ENU toxicity (0.82 6 0.225%) when compared with normal cells (0.32 6 0.055%). In ET1 (3.92 6 0.56%), cytochrome c expression increased significantly followed by further heightened expression in ET2 (6.59 6 0.98%). In the third and final dose (5.40 60.57%), the value decreased very slightly when compared with second dose but was significantly higher as compared with normal, ENU and ET1 (P < 0.01) groups (Fig. 6AI-AV) . For BIL, significant rise in cytochrome c expression was observed in ENU (2.44 6 0.505%) when compared with normal cells (0.9 6 0.22%). With first dose (2.75 6 0.56%), cytochrome c expression increased insignificantly as compared Fig. 4 . Bax expression of the three cells viz glioma, BIL and microglia was assayed to find out its pro-apoptotic role in T11TS-mediated specific apoptosis of the tumor cells and of its role if any in the regulatory death of the BIL and Mg. Interestingly, maximal Bax expression was found with the second dose of T11TS in all the three cell types. (A.I) Brain cells of normal animals (normal glial cells 29.39 6 1.82%), (A.II) brain tumor cells of 7-month-old ENU (ENU 21.18 6 1.62%), (A.III) cells isolated from animals after administration of first dose of T11TS in 7-month-old tumorbearing animals (ET1 38.21 6 2.25%), (A.IV) cells isolated from animals after administration of two booster dose of T11TS at 6-day interval (ET2 67.51 6 4.67%) and (A.V) cells isolated from animals after administration of three booster dose at 6-day interval (ET3 54.16 6 3.18%). (B.I) BILs isolated form normal animals (normal BIL 44.16 6 3.01%), (B.II) BIL isolated from ENU (ENU BIL 57.64 6 3.99%), (B.III) BIL isolated from ET1 animals (ET1 BIL 65.63 6 4.25%), (B.IV) BIL isolated from ET2 animals (ET2 BIL 72.67 6 5.12%) and (B.V) BIL isolated from ET3 animals (ET3 BIL 62.71 6 4.05%). (C.I) Microglia isolated form normal animals (normal microglia 44.99 6 3.01%), (C.II) microglia isolated from ENU (ENU microglia 57.61 6 1.01%), (C.III) microglia isolated from ET1 animals (ET1 microglia 58.5 6 4.11%), (C.IV) microglia isolated from ET2 animals (ET2 microglia 76.59 6 5.28%) and (C.V) microglia isolated from ET3 animals (ET3 microglia 68.69 6 4.96%).
with ENU, followed by further increase in ET2 (4.21 6 0.71%). In ET3 (3.51 6 0.63%), the value decreased significantly when compared with ET2 but was still significantly higher as compared with normal ( Fig. 6BI-BV) .
In case of microglial cells also, cytochrome c increased significantly in ENU (2 6 0.31%) when compared with normal cells (1.21 6 0.24%). In ET1 dose (2.24 6 0.43%), cytochrome c expression increased insignificantly as compared with ENU, after which it increased significantly in ET2 (4.18 6 0.57%). In ET3 (3.5 6 0.49%), the expression level of cytochrome c further decreased when compared with ET2 group but was significantly higher (P < 0.001) as compared with normal and ENU groups (Fig. 6CI-CV) . All the three cells showed similar expression pattern where maximal 11% ), (C.II) microglia isolated from ENU (ENU microglia 5.15 6 1.01%), (C.III) microglia isolated from ET1 animals (ET1 microglia 7.38 6 1.08%), (C.IV) microglia isolated from ET2 animals (ET2 microglia 14.97 6 1.18%) and (C.V) microglia isolated from ET3 animals (ET3 microglia 16.69 6 1.19%).
expression of cytochrome c was mainly observed with the first and second dose of T11TS administration. The expression level clearly lowers in the final dose but is still significantly higher than normal counter parts.
Apaf-1 protein expression. Once mitochondrial release of cytochrome c occurs, it now enters into the cytosol and forms a complex with another molecule, Apaf-1, thereby increasing Apaf-1's affinity for dATP/ATP by ;10-fold. The binding of nucleotide to the Apaf-1-cytochrome c complex triggers its oligomerization to form the apoptosome, a multimeric wheellike Apaf-1 and cytochrome c complex. Therefore, we next examined Apaf-1 expression. In case of brain tumor cells, a significant rise in Apaf-1 expression was observed in Fig. 6 . In case of all the three cell types viz brain tumor cells, BIL and microglia, a surge in cytochrome c expression is observed in second dose of T11TS after which the expression level decreases slightly but is still higher than the normal level. (A.I) Brain cells of normal animals (normal glial cells 0.32 6 0.055%), (A.II) brain tumor cells of 7-month-old ENU (ENU 0.82 6 0.225%), (A.III) cells isolated from animals after administration of first dose of T11TS in 7-month-old tumor-bearing animals (ET1 3.92 6 0.56%), (A.IV) cells isolated from animals after administration of two booster dose of T11TS at 6-day interval (ET2 6.59 6 0.98%) and (A.V) cells isolated from animals after administration of three booster dose at 6-day interval (ET3 5.40 6 0.57%). (B.I) BILs isolated form normal animals (normal BIL 0.9 6 0.22%), (B.II) BIL isolated from ENU (ENU BIL 2.44 6 0.505%), (B.III) BIL isolated from ET1 animals (ET1 BIL 2.75 6 0.56%), (B.IV) BIL isolated from ET2 animals (ET2 BIL 4.21 6 0.71%) and (B.V) BIL isolated from ET3 animals (ET3 BIL 3.51 6 0.63%). (C.I) Microglia isolated form normal animals (normal microglia 1.21 6 0.24%), (C.II) microglia isolated from ENU (ENU microglia 2 6 0.31%), (C.III) microglia isolated from ET1 animals (ET1 microglia 2.24 6 0.43%), (C.IV) microglia isolated from ET2 animals (ET2 microglia 4.18 6 0.57%) and (V) microglia isolated from ET3 animals (ET3 microglia 3.5 6 0.49%).
tumor-bearing group (2.22 6 0.49%) when compared with normal cells (0.98 6 0.28%). The expression of Apaf-1 further increases significantly (P < 0.001) with the three consecutive doses of T11TS, as compared with normal and ENU (ET1 4.56 6 0.51%, ET2 6.59 6 0.66% and ET3 5.47 6 0.57%). However, maximal expression of Apaf-1 was observed in the second dose (Fig. 7AI-AV) .
For BIL, a significant (P < 0.01) increase in Apaf-1 expression was observed in ENU (4.58 6 0.505%) when compared with normal cells (1.37 6 0.225%). Following the same trend of expression as in glioma cells, Apaf-1 expression increased significantly (P < 0.001) from ET1 to ET2 to ET3 (ET1 9.58 6 0.56%, ET2 14.7 6 0.835% and ET3 10.4 6 0.505%) as compared with N and ENU where maximal Fig. 7 . In case of all the three cell types viz brain tumor cells, BIL and microglia, a surge in Apaf-1 expression is observed in first and second dose of T11TS after which the expression level decreases slightly but is still higher than the normal level. (A.I) Brain cells of normal animals (normal glial cells 0.98 6 0.28%), (A.II) brain tumor cells of 7-month-old ENU (ENU 2.22 6 0.49%), (A.III) cells isolated from animals after administration of first dose of T11TS in 7-month-old tumor-bearing animals (ET1 4.56 6 0.51%), (A.IV) cells isolated from animals after administration of two booster dose of T11TS at 6-day interval (ET2 6.59 6 0.66%) and (A.V) cells isolated from animals after administration of three booster dose at 6-day interval (ET3 5.47 6 0.57%). (B.I) BILs isolated form normal animals (normal BIL 1.37 6 0.225%), (B.II) BIL isolated from ENU (ENU BIL 4.58 6 0.505%), (B.III) BIL isolated from ET1 animals (ET1 BIL 9.58 6 0.56%), (B.IV) BIL isolated from ET2 animals (ET2 BIL 14.7 6 0.835%) and (B.V) BIL isolated from ET3 animals (ET3 BIL 10.4 6 0.505%). (C.I) Microglia isolated form normal animals (normal microglia 1.86 6 0.105%), (C.II) microglia isolated from ENU (ENU microglia 3.10 6 0.195%), (C.III) microglia isolated from ET1 animals (ET1 microglia 4.80 6 0.345%), (C.IV) microglia isolated from ET2 animals (ET2 microglia 6.11 6 0.48%) and (C.V) microglia isolated from ET3 animals (ET3 microglia 5.78 6 0.435%). significant (P < 0.001) expression was found in ET2 as compared with ET1 and ET3 (Fig. 7BI-BV) .
In case of microglial cell also Apaf-1 increased significantly in tumor cells as compared with normal. With T11TS administration, significant rise in Apaf-1 expression was observed in ET1 / ET2 / ET3 (ET1 4.80 6 0.345%, ET2 6.11 6 0.48% and ET3 5.78 6 0.435%) as compared with N (1.86 6 0.105%) and ENU (3.10 6 0.195%) where maximal significant (P < 0.001) expression was found in ET2 as compared with ET1 and ET3 (Fig. 7CI-CV) . Here also we do observe a stark similarity in expression pattern of Apaf-1 in the three cell types. In fact, the expression pattern of Apaf-1 very much followed the expression pattern of cytochrome c in all the three interacting cells where we get a peak expression of both these apoptosomal protein in first and second dose of T11TS.
Western blot analysis Bid protein expression. Since cleavage of cytosolic p22 Bid by caspase-8 generates an active p15 C-terminal fragment that translocates to the mitochondria, we did WB analysis of Bid to ensure the production of activated Bid. In case of glioma, the inactive 22-kDa full-length Bid was observed in normal group (N), ENU, ET2 and ET3. In ET1 dose, the active large fragment of Bid i.e. tBid was observed at 15 kDa (Fig. 8A) .
In case of BIL, the inactive 25-kDa full-length Bid was observed in normal group (N), ENU, ET2 and ET3. In ET1 dose, the active large fragment of Bid i.e. tBid was observed at 17 kDa (Fig. 8B) .
In case of microglia, the inactive 24-kDa full-length Bid was observed in normal group (N), ENU, ET2 and ET3. In ET1 dose, the active large fragment of Bid i.e. tBid was observed at 18 kDa (Fig. 8C) . Thus, the observation of active tBid with the first dose of administration of T11TS in all the three cells clearly indicated that activated tBid was now targeting the mitochondria to amplify the apoptotic signals.
Caspase-9 protein expression. As inactive caspase-9 is recruited to the apoptosome and processed to form the active caspase-9, we next analyzed caspase-9 by WB to judge its involvement. In case of glioma, the inactive 51-kDa proform was observed in normal group (N). Caspase-9 activation was assessed by the observation of the 39-kDa active caspase-9 subunit in ENU, ET1, ET2 and ET3 groups (Fig. 9A) .
In case of BIL, the inactive 48-kDa proform was observed in normal group (N), ENU and ET1. In ET2 and ET3 dose, the active proform of caspase-9 was seen at 39 kDa (Fig. 9B) .
In case of microglia, the inactive 51-kDa proform was observed in normal (N) and tumor-bearing group (ENU) and ET1. In ET2 and ET3 dose, the active proform of caspase-9 was seen at 38 kDa (Fig. 9C) . In case of the two interacting immunocytes, presence of active caspase-9 in the second and the third dose of T11TS indicates the formation of apoptosome in the said doses. But in case of glioma cells, formation of apoptosome seems to have occurred in the untreated tumor-bearing group (ENU) and in all the groups receiving the three consecutive doses of T11TS (ET1, ET2 and ET3).
Caspase-3 protein expression. The ultimate downstream effector caspase that is catalytically cleaved and activated by caspase-9 is caspase-3. Therefore, the next caspase that we studied was caspase-3. The inactive 32-kDa proform of caspase-3 was observed in normal group (N). Caspase-3 activation was assessed by the observation of the 22-kDa active subunit of caspase-3 in ENU, ET1, ET2 and ET3 groups (Fig. 10A) .
In case of BIL, the inactive 32-kDa proform of caspase-3 was observed in normal group (N), ENU and ET2. In ET1 and ET3 dose, the active caspase-3 enzyme was seen at 17 kDa (Fig. 10B) .
In case of microglia, the inactive 32-kDa caspase-3 proenzyme was observed in normal group (N) and tumor-bearing group (ENU). In ET1, ET2 and ET3 groups, the active caspase-3 proform was seen at 17 kDa (Fig. 10C) . The expression of active caspase-3 in tumor-bearing group and in all the treated groups of glioma cells clearly hints at one to one relation between caspase-9 and caspse-3 where the former directly activates the latter. In case of BIL, in the final dose of T11TS, we do observe the linear cascade of caspase-9 followed by caspase-3 activation. In the microglial cells, it is in the second and the third dose that both the proteins are simultaneously activated.
The loading control for all the proteins was b-actin. However, the b-actin bands were not always at the same level as the electric field and the protein migration was not same in all parts of the gel probably due to non-uniformity of the gel structure.
Discussion
Our previous studies had pointed out the involvement of DRs and caspase-8 in all the three cells types. In case of glioma cells, the DR pathway (Fas / FasL / caspase-8) was operative in the second and third dose while in BILs the pathway was operative in the first and the third dose. But in microglia, the Fas-FasL pathway was operative in the first dose only. Naturally, when the effector caspase-3 of the three cell types were analyzed, the involvement of other apoptotic regulators was evident. For the purpose, we thus went on to study the involvement of the Bcl-2 family of proteins that included the pro-apoptotic Bid and Bax and the antiapoptotic Bcl-2; the cell cycle/cell death regulator p53 and the apoptosomal proteins: cytochrome c, Apaf-1 and caspase-9.
In the glioma cells, Bcl-2 family BH3 protein-Bid was only activated on administration of first dose of T11TS, which now simultaneously proceeded to insert into mitochondrial membrane on one hand as well as to target and activate Bax on the other hand. Concurrently, in the same dose p53 was activated which in turn targets and activates Bax. Bax protein is a p53 target and a pro-apoptotic member of the Bcl-2 family (33, 34) . Thus, dual activation of Bax by p53 and Bid Fig. 9 . Western blot analysis of caspase-9 in the three interacting cells. (A) The inactive 51-kDa proform was observed in normal group (N). Caspase-9 activation was assessed by the observation of the 39-kDa subunit in ENU, ET1, ET2 and ET3 groups. (B) In case of BIL, the inactive 48-kDa proform was observed in normal group (N), ENU and ET1. In ET2 and ET3 dose, the active proform is seen at 39 kDa. (C) In case of microglia, the inactive 51-kDa proform was observed in normal group (N) and tumor-bearing group (ENU) and ET1. In ET2 and ET3 dose, the active proform is seen at 38 kDa. (B) In BIL, the inactive 32-kDa proform is observed in normal group (N), ENU and ET2. In ET1 and ET3 dose, the active proform is seen at 17 kDa. (C) In case of microglia, the inactive 32-kDa proform was observed in normal group (N) and ENU. In ET1, ET2 and ET3 groups, the active proform is seen at 17 kDa.
heightened the expression level of Bax in the first and maximally in the second dose, whereas the Bcl-2 protein expression seems to be totally down-regulated (Fig. 11A,  Fig. 3AI-AV, Fig. 4AI-AV, Fig. 5AI-AV) . The Bax/Bcl-2 ratio now hangs in favor of Bax and the mitochondrial membrane integrity seems to be jeopardized as was observed by the significant rise in cytochrome c in ET1 followed by maximal expression in the second dose. Another apoptosomal protein Apaf-1 expression also increased where maximal expression of the protein was observed in the second dose (Fig. 11B, Fig. 6AI-AV, Fig. 7AI-AV) . Caspase-9 was recruited to this complex where it was cleaved to form active caspase-9, which proceeded to activate caspase-3 in the second dose. Distinct involvement of the mitochondria was thus obvious with the second dose itself. The band of active caspase-9, as observed by western blotting in the second dose, further intensified with the third dose, thereby acting as a clear indicator of more intense mitochondrial involvement. However, a very faint band of active caspase-9 and active caspase-3 was also observed in tumor-bearing group and in the first dose indicating apoptosis via the involvement of mitochondria in the said doses. Initial low-level apoptosis in untreated group involving the mitochondria can be totally attributed to the body's immune surveillance.
In the BILs, on administration of first dose of T11TS, Bax is dually activated by Bid and p53 in a similar fashion as was in the case of glioma cells. Interestingly, in the same dose a significant rise in Bcl-2 expression stabilizes the cells favoring survival (Fig. 12A, Fig. 3BI-BV, Fig. 4BI-BV,  Fig. 5BI-BV) . This notion could be further adjudicated by the fact that in the first dose even though cytochrome c and Apaf-1 expression was higher than the normal controls but no band of active caspase-9 was observed. Thus, Bcl-2 was successful in controlling the internal mileu of the cell under its reigns. However, our previous results along with presence of active caspase-3 in the first dose clearly indicate the involvement of DRs being operative in the said dose. With the administration of the second dose, an evident drop in Bcl-2 level and rise in Bax expression occurs thus priming the internal milieu of the cell in favor of Bax which now targets the mitochondrial membrane. Evidence of functional apoptosome could be observed from the presence of a very low intensity band of active caspase-9 in the second dose (Fig. 12B, Fig. 6BI-BV, Fig. 7BI-BV) . But again no active caspase-3 was found in the second dose. Notably, drop in Bcl-2 level, rise in Bax expression and presence of active caspase-9 indicating mitochondrial involvement in ET2 dose thus primes the internal milieu of the cell favoring death but a significant low-level p53 expression seems to be the controlling point that prevents BIL from undergoing apoptosis in the said dose. In the final dose, the deprivation of the microenvironment from tumor antigens thus sends further cues to BIL and the mitochondrial membrane integrity in this case being targeted alone by Bax. Formation of the apoptosome occurs where procaspase-9 is processed to active caspase-9, which proceeds to activate caspase-3. Interestingly, in case of BIL, in the three treated doses of T11TS, three death regulators seem to play protagonistic role in controlling the internal mileu. In ET1 dose, it is Bcl-2, in the ET2 dose it is p53 and in the ET3 dose it is Bax. However, in case of BIL, switching on the apoptotic cascades occurs in those infiltrated lymphocytes that have been damaged or in those cells (mainly in the final dose) which need to be down-regulated as the tumor mass has been reduced and normal homeostasis needs to be regained.
Microglial apoptotic pattern very much simulated BIL's apoptotic pattern with the exception of the fact that the apoptotic cascade within microglia was operative in all three treated dose of T11TS. In the first dose itself, Bid was activated which proceeds to insert into mitochondrial membrane and simultaneously activate Bax. Rise in p53 expression also results in Bax activation. But on the other hand, rise in Bcl-2 expression overrides the antagonizing action of p53 and Bax thus favoring survival of the microglial population in the ET1 dose at least at the mitochondrial level (Fig. 13A, Fig. 3CI -CV, Fig. 4CI -CV, Fig. 5CI-CV) . This view could be aptly solicitated by the fact that we do not observe any active caspase-9 band in the said dose. But the DR pathway was very much operative in ET1. However, with the second and third dose of T11TS, rise in Bax expression now overpowers the survival effect of BIL, thereby bringing mitochondria within the purview of death. Apoptosome formation occurs resulting in formation of active caspase-9 and active caspase-3 band in the second and third dose and hence microglial death (Fig. 13B, Fig. 6CI-CV, Fig. 7CI-CV) . Microglia being a homeostatic population, the survival instincts of microglia were higher and the regulatory apoptosis that occurred within this cell population was very minimal. A continuous renewal of microglial population occurred within the brain parenchyma thereby maintaining a steady pool of the microglial population. In case of Mg, it should also be noted that switching on the apoptotic cascades occurred in those cells that have been damaged due to interaction with the tumor mass or due to initial tumor counter-attack. Moreover, some amount of regulatory apoptosis occurs in the final dose to bring down the activated population of microglia. Thus, in glioma cells, the involvement of mitochondria was evident in all the treated groups and to some extent in the untreated group. T11TS in the process of implementing cell death to the tumor cells also conducts minimal apoptotic death of the immunocytes mainly due to two reasons. On one hand, the immunocytes die primarily due to tumor counter-attack as well as due to direct interaction of the immunocytes with the target tumor cells while on the other hand regulatory death of the interacting immunocytes by way of apoptosis occurs in the final dose to bring down the level of activated immunocytes thereby restoring the immune homeostasis within the brain parenchyma. In the second and third dose in case of microglia and in third dose in case of BIL, the activated immunocytes die by passive cell death due to paucity of tumor antigens (as majority of tumor cells have already undergone apoptotic death). Under such condition, mitochondrial membrane integrity is lost with the release of cytochrome c and the intrinsic regulators are brought into action. 
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